Takeda Pharmaceutical Company Limited 보도자료
Takeda Showcases Continued Commitment in Hodgkin Lymphoma During 10th International Symposium on Hodgkin Lymphoma (ISHL)
10월 19일 10:05
Takeda Pharmaceutical Company Limited (TSE: 4502) will present data on ADCETRIS® (brentuximab vedotin) in Hodgkin lymphoma at the 10th International Symposium on Hod...
Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m
10월 11일 10:50
Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody®-based therapeutics, and Takeda Pharmaceutical Company Limited (TSE: 4502) toda...
Takeda and Zydus Cadila partner to address the global threat of Chikungunya
09월 21일 14:00
Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) and Zydus Cadila today announced a partnership to tackle chikungunya, an emerging infectious disease in...
Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLARO™ (ixazomib), the First Oral Proteasome Inhibitor, for Use in Patients with Multiple Myeloma
09월 19일 10:10
Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ha...
Takeda Supports Global Expansion of the American Cancer Society’s Relay For Life (RFL)
09월 13일 11:40
RFL is the largest grassroots fundraiser in the world and currently brings together cancer communities in more than 26 countries. Through this expansion, RFL expects...
Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003)
09월 08일 10:25
Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that it has vaccinated the first subject in the Tetravalent Immunization against Dengue...
Takeda to develop Zika Vaccine with up to $312 million in funding from US Government
09월 02일 10:10
Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that BARDA, the Biomedical Advanced Research and Development Authority, has selected Ta...
Takeda Launches Largest Pharmaceutical Company-Sponsored Global Observational Study of Its Kind in Multiple Myeloma
09월 01일 14:05
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that its global non-interventional, observational multiple myeloma study is now enrolling patients....
Takeda Announces Bold, New Access to Medicines Strategy
08월 29일 11:20
Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced the launch of a bold, new Access to Medicines (AtM) strategy, aimed at increasing access to its in...
다케다제약, 과감하고 새로운 의약품 접근성 전략 발표
08월 29일 11:20
다케다제약(Takeda Pharmaceutical Company Limited)(도쿄증권거래소: 4502)이 미 충족 의료 요구가 가장 높은 일부 환자들을 위한 혁신적이고 잠재적으로 생명을 구할 수 있는 의약품에 대한 접근성을 확대하는 것을 목표로 하는 과감하고 새로운 의약품 접근성(Access...
Takeda Receives Marketing Authorization in Canada for NINLARO™(ixazomib) in Relapsed/Refractory Multiple Myeloma
08월 09일 09:41
Takeda Pharmaceutical Company Limited (TSE:4502) today announced Takeda Canada has received approval from Health Canada for NINLARO™ (ixazomib) capsules in combinati...
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
08월 01일 19:55
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the Phase 3 ALCANZA clinical trial evaluating ADCETRIS...
다케다와 시애틀 제네틱스, ‘애드세트리스’(브렌툭시맙 베도틴)의 CD30발현 피부T세포 림프종 환자 대상 3상 ALCANZA 임상시험의 긍정적 결과 발표
08월 01일 19:55
다케다제약(Takeda Pharmaceutical Company Limited)(도쿄증권거래소: 4502)과 시애틀 제네틱스(Seattle Genetics, Inc.)(나스닥: SGEN)가 피부T세포 림프종(CTCL)환자를 대상으로 실시한 ‘애드세트리스’(ADCETRIS)(성분명: 브렌툭시맙 베...
Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and Confidence in Management Guidance
08월 01일 10:40
Takeda Pharmaceutical Company Limited (TOKYO:4502): Strong first quarter results and confidence in Management Guidance · Underlying revenue grew +9.1%, driven by...
다케다, 한 해의 튼실한 시작과 경영 지침에 대한 자신감으로 2016회계연도 1분기 실적 발표
08월 01일 10:40
다케다제약(Takeda Pharmaceutical Company Limited) (도쿄증권거래소: 4502): 1분기에 튼실한 실적과 경영 지침에 대한 자신감 달성 · 다케다의 성장 동력(위장관[GI] 질환, 종양, 중추신경계[CNS] 질환 치료제 및 신흥시장) 매출이 15.3% 증가...
1 2 3 4 5 6 7 >
Takeda Pharmaceutical Company Limited
상장여부 : 비상장
본사 소재지 : OSAKA, Japan
업종: 건강-제약
기업 개요:
등록된 회사소개가 없습니다.